Baggen J, Jacquemyn M, Persoons L, Vanstreels E, Pye V, Wrobel A, et al. TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry. Cell. 2023;: pubmed publisher

Mahalingam G, Arjunan P, Periyasami Y, Dhyani A, Devaraju N, Rajendiran V, et al. Correlating the differences in the receptor binding domain of SARS-CoV-2 spike variants on their interactions with human ACE2 receptor. Sci Rep. 2023;13:8743 pubmed publisher

Garc xed a Murria M, Gadea Salom L, Moreno S, Rius Salvador M, Zaragoza O, Brun A, et al. Identification of small molecules capable of enhancing viral membrane fusion. Virol J. 2023;20:99 pubmed publisher

Luo S, Moussa E, López Orozco J, Felix Lopez A, Ishida R, Fayad N, et al. Identification of Human Host Substrates of the SARS-CoV-2 Mpro and PLpro Using Subtiligase N-Terminomics. ACS Infect Dis. 2023;9:749-761 pubmed publisher

Bednash J, Johns F, Farkas D, Elhance A, Adair J, Cress K, et al. Inhibiting the Deubiquitinase UCHL1 Reduces SARS-CoV-2 Viral Uptake by ACE2. Am J Respir Cell Mol Biol. 2023;68:566-576 pubmed publisher

Harte J, Wakerlin S, Lindsay A, McCarthy J, Coleman Vaughan C. Metalloprotease-Dependent S2'-Activation Promotes Cell-Cell Fusion and Syncytiation of SARS-CoV-2. Viruses. 2022;14: pubmed publisher

Mannar D, Saville J, Sun Z, Zhu X, Marti M, Srivastava S, et al. SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization. Nat Commun. 2022;13:4696 pubmed publisher

Battulin N, Korablev A, Ryzhkova A, Smirnov A, Kabirova E, Khabarova A, et al. The human EF1a promoter does not provide expression of the transgene in mice. Transgenic Res. 2022;31:525-535 pubmed publisher

Aggarwal A, Stella A, Walker G, Akerman A, Esneau C, Milogiannakis V, et al. Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia. Nat Microbiol. 2022;7:896-908 pubmed publisher

Rosendal E, Mihai I, Becker M, Das D, Frängsmyr L, Persson B, et al. Serine Protease Inhibitors Restrict Host Susceptibility to SARS-CoV-2 Infections. MBio. 2022;13:e0089222 pubmed publisher

Lee R, Li T, Chang S, Chao T, Kuo C, Pan M, et al. Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2. Int J Mol Sci. 2022;23: pubmed publisher

Ahamad S, Ali H, Secco I, Giacca M, Gupta D. Anti-Fungal Drug Anidulafungin Inhibits SARS-CoV-2 Spike-Induced Syncytia Formation by Targeting ACE2-Spike Protein Interaction. Front Genet. 2022;13:866474 pubmed publisher

Jang K, Kaczmarek M, Dallari S, Chen Y, Tada T, Axelrad J, et al. Variable susceptibility of intestinal organoid-derived monolayers to SARS-CoV-2 infection. PLoS Biol. 2022;20:e3001592 pubmed publisher

Peng L, Hu Y, Mankowski M, Ren P, Chen R, Wei J, et al. Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617. Nat Commun. 2022;13:1638 pubmed publisher

Lee S, Kim D, Jung Y. Construction of SARS-CoV-2 spike-pseudotyped retroviral vector inducing syncytia formation. Virus Genes. 2022;58:172-179 pubmed publisher

Clark N, Janaka S, Hartman W, Stramer S, Goodhue E, Weiss J, et al. Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection. PLoS ONE. 2022;17:e0257930 pubmed publisher

Liu J, Lu F, Chen Y, Plow E, Qin J. Integrin mediates cell entry of the SARS-CoV-2 virus independent of cellular receptor ACE2. J Biol Chem. 2022;298:101710 pubmed publisher

Balachandran H, Phetsouphanh C, Agapiou D, Adhikari A, Rodrigo C, Hammoud M, et al. Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses. Cell Rep. 2022;38:110345 pubmed publisher

Kim H, Cho J, Kim E, Kim J, Yang J, Kim K, et al. Engineered small extracellular vesicles displaying ACE2 variants on the surface protect against SARS-CoV-2 infection. J Extracell Vesicles. 2022;11:e12179 pubmed publisher

Cui Q, Garcia G, Zhang M, Wang C, Li H, Zhou T, et al. Compound screen identifies the small molecule Q34 as an inhibitor of SARS-CoV-2 infection. iScience. 2022;25:103684 pubmed publisher

Raymonda M, Ciesla J, Monaghan M, Leach J, Asantewaa G, Smorodintsev Schiller L, et al. Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro. Virology. 2022;566:60-68 pubmed publisher

Castiglione G, Zhou L, Xu Z, Neiman Z, Hung C, Duh E. Evolutionary pathways to SARS-CoV-2 resistance are opened and closed by epistasis acting on ACE2. PLoS Biol. 2021;19:e3001510 pubmed publisher

Valero J, Civit L, Dupont D, Selnihhin D, Reinert L, Idorn M, et al. A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry. Proc Natl Acad Sci U S A. 2021;118: pubmed publisher

Ashhurst A, Tang A, Fajtová P, Yoon M, Aggarwal A, Bedding M, et al. Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L. J Med Chem. 2021;: pubmed publisher

Sohn S, Hearing J, Mugavero J, Kirillov V, Gorbunova E, Helminiak L, et al. Interferon-Lambda Intranasal Protection and Differential Sex Pathology in a Murine Model of SARS-CoV-2 Infection. MBio. 2021;12:e0275621 pubmed publisher

Tea F, Ospina Stella A, Aggarwal A, Ross Darley D, Pilli D, Vitale D, et al. SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants. PLoS Med. 2021;18:e1003656 pubmed publisher

Zhao M, Su P, Castro D, Tripler T, Hu Y, Cook M, et al. Rapid, reliable, and reproducible cell fusion assay to quantify SARS-Cov-2 spike interaction with hACE2. PLoS Pathog. 2021;17:e1009683 pubmed publisher

Gutmann C, Takov K, Burnap S, Singh B, Ali H, Theofilatos K, et al. SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care. Nat Commun. 2021;12:3406 pubmed publisher

Bartolomé A, Liang J, Wang P, Ho D, Pajvani U. Angiotensin converting enzyme 2 is a novel target of the γ-secretase complex. Sci Rep. 2021;11:9803 pubmed publisher

Janaka S, Hartman W, Mou H, Farzan M, Stramer S, Goodhue E, et al. Donor Anti-Spike Immunity is Related to Recipient Recovery and Can Predict the Efficacy of Convalescent Plasma Units. medRxiv. 2021;: pubmed publisher

Baggen J, Persoons L, Vanstreels E, Jansen S, Van Looveren D, Boeckx B, et al. Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2. Nat Genet. 2021;53:435-444 pubmed publisher

Daniloski Z, Jordan T, Ilmain J, Guo X, Bhabha G, tenOever B, et al. The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types. elife. 2021;10: pubmed publisher

Powell A, Zhang K, Sanyal M, Tang S, Weidenbacher P, Li S, et al. A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice. ACS Cent Sci. 2021;7:183-199 pubmed publisher

Zhu J, Ananthaswamy N, Jain S, Batra H, Tang W, Lewry D, et al. A Universal Bacteriophage T4 Nanoparticle Platform to Design Multiplex SARS-CoV-2 Vaccine Candidates by CRISPR Engineering. bioRxiv. 2021;: pubmed publisher

Tan T, Rijal P, Rahikainen R, Keeble A, Schimanski L, Hussain S, et al. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Nat Commun. 2021;12:542 pubmed publisher

Schweitzer K, Crue T, Nall J, Foster D, Sajuthi S, Correll K, et al. Influenza virus infection increases ACE2 expression and shedding in human small airway epithelial cells. Eur Respir J. 2021;: pubmed publisher

Clausen T, Sandoval D, Spliid C, Pihl J, Perrett H, Painter C, et al. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. Cell. 2020;: pubmed publisher

Daniloski Z, Guo X, Sanjana N. The D614G mutation in SARS-CoV-2 Spike increases transduction of multiple human cell types. bioRxiv. 2020;: pubmed publisher

Dieterle M, Haslwanter D, Bortz R, Wirchnianski A, Lasso G, Vergnolle O, et al. A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition. bioRxiv. 2020;: pubmed publisher

Li W, Moore M, Vasilieva N, Sui J, Wong S, Berne M, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450-4 pubmed